These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 39338397)

  • 1. Intravitreal Dexamethasone Implant in Anti-Vascular Endothelial Growth Factor Pretreated Diabetic Macular Edema-A Swiss Cohort Study.
    Turgut F; Somfai GM; Tappeiner C; Hatz K; Mantel I; Ambresin A; Donati G; Guignard V; Nagyová D; Pfister IB; Schild C; Garweg JG
    Pharmaceuticals (Basel); 2024 Sep; 17(9):. PubMed ID: 39338397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema.
    He Y; Ren XJ; Hu BJ; Lam WC; Li XR
    BMC Ophthalmol; 2018 May; 18(1):121. PubMed ID: 29784048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema.
    Busch C; Zur D; Fraser-Bell S; Laíns I; Santos AR; Lupidi M; Cagini C; Gabrielle PH; Couturier A; Mané-Tauty V; Giancipoli E; Ricci GD; Cebeci Z; Rodríguez-Valdés PJ; Chaikitmongkol V; Amphornphruet A; Hindi I; Agrawal K; Chhablani J; Loewenstein A; Iglicki M; Rehak M;
    Acta Diabetol; 2018 Aug; 55(8):789-796. PubMed ID: 29730822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world outcomes of non-responding diabetic macular edema treated with continued anti-VEGF therapy versus early switch to dexamethasone implant: 2-year results.
    Busch C; Fraser-Bell S; Iglicki M; Lupidi M; Couturier A; Chaikitmongkol V; Giancipoli E; Rodríguez-Valdés PJ; Gabrielle PH; Laíns I; Santos AR; Cebeci Z; Amphornphruet A; Degenhardt V; Unterlauft JD; Cagini C; Mané-Tauty V; D'Amico Ricci G; Hindi I; Agrawal K; Chhablani J; Loewenstein A; Zur D; Rehak M;
    Acta Diabetol; 2019 Dec; 56(12):1341-1350. PubMed ID: 31541334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dexamethasone intravitreal implant in diabetic macular oedema refractory to anti-vascular endothelial growth factors: the AUSSIEDEX study.
    Mitchell P; Arnold J; Fraser-Bell S; Kang HK; Chang AA; Tainton J; Simonyi S
    BMJ Open Ophthalmol; 2023 Aug; 8(1):. PubMed ID: 37541745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of dexamethasone intravitreal implant in patients with retinal vein occlusion resistant to anti-VEGF therapy: a 12-month prospective study.
    Georgalas L; Tservakis I; Kiskira EE; Petrou P; Papaconstantinou D; Kanakis M
    Cutan Ocul Toxicol; 2019 Dec; 38(4):330-337. PubMed ID: 31060385
    [No Abstract]   [Full Text] [Related]  

  • 7. Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema.
    Mehta H; Hennings C; Gillies MC; Nguyen V; Campain A; Fraser-Bell S
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011599. PubMed ID: 29669176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Diabetic Macular Edema with Multiple Dexamethasone Intravitreal Implants: Evidence from Real-Life Experience.
    De Geronimo D; Giorno P; Scarinci F; Boninfante A; Varano M; Parravano M
    Ophthalmologica; 2020; 243(6):413-419. PubMed ID: 31760387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal steroids for macular edema in diabetes.
    Rittiphairoj T; Mir TA; Li T; Virgili G
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005656. PubMed ID: 33206392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Intravitreal Dexamethasone Implant in the Management of Treatment-Naive Diabetic Macular Edema: A Pre-Cataract Surgical Approach for Patients with Systemic Contraindications to Anti-VEGF Therapy.
    Chakraborty S; Ganguly S; Sheth JU
    Clin Ophthalmol; 2024; 18():227-233. PubMed ID: 38283181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal dexamethasone insert in diabetic macular edema super-refractory to anti-vascular endothelial growth factor therapy.
    Wilkins CS; Sobol EK; Lema GM; Lee JG; Rosen RB; Deobhakta A
    Eur J Ophthalmol; 2022 Sep; 32(5):NP37-NP41. PubMed ID: 33757333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world assessment of intravitreal dexamethasone implant (0.7 mg) in patients with macular edema: the CHROME study.
    Lam WC; Albiani DA; Yoganathan P; Chen JC; Kherani A; Maberley DA; Oliver A; Rabinovitch T; Sheidow TG; Tourville E; Wittenberg LA; Sigouin C; Baptiste DC
    Clin Ophthalmol; 2015; 9():1255-68. PubMed ID: 26203215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of Intravitreal Dexamethasone Implant Treatment for Diabetic Macular Edema in Vitrectomized Eyes.
    Özdemir HB; Hasanreisoğlu M; Yüksel M; Ertop M; Gürelik G; Özdek Ş
    Turk J Ophthalmol; 2019 Dec; 49(6):323-327. PubMed ID: 31893587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of dexamethasone intravitreal implant with intravitreal anti-VEGF injections for the treatment of macular edema secondary to branch retinal vein occlusion: A meta-analysis.
    Ji K; Zhang Q; Tian M; Xing Y
    Medicine (Baltimore); 2019 May; 98(22):e15798. PubMed ID: 31145307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of a Dexamethasone Implant in Patients with Diabetic Macular Edema at Tertiary Centers in Korea.
    Moon BG; Lee JY; Yu HG; Song JH; Park YH; Kim HW; Ji YS; Chang W; Lee JE; Oh J; Chung I
    J Ophthalmol; 2016; 2016():9810270. PubMed ID: 27293879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and long-term efficacy of repeated dexamethasone intravitreal implants for the treatment of cystoid macular edema secondary to retinal vein occlusion with or without a switch to anti-VEGF agents: a 3-year experience.
    Blanc J; Deschasse C; Kodjikian L; Dot C; Bron AM; Creuzot-Garcher C
    Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1441-1448. PubMed ID: 29855706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does HbA1c Level or Glomerular Filtration Rate Affect the Clinical Response to Endothelial Growth Factor Therapy (Ranibizumab or Aflibercept) in Diabetic Macular Edema? A Real-Life Experience.
    Debourdeau E; Medard R; Chamard C; Nguyen V; Gabrielle PH; Creuzot-Garcher C; Allieu S; Gillies MC; Barthelmes D; Daien V;
    Ophthalmol Ther; 2023 Oct; 12(5):2657-2670. PubMed ID: 37505396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VISUAL OUTCOMES IN PATIENTS WITH DIABETIC MACULAR EDEMA TREATED WITH DEXAMETHASONE IMPLANT IN ROUTINE CLINICAL PRACTICE.
    Urbančič M; Gardašević Topčić I; Matović K
    Acta Clin Croat; 2021 Dec; 60(4):602-608. PubMed ID: 35734494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study.
    Augustin AJ; Kuppermann BD; Lanzetta P; Loewenstein A; Li XY; Cui H; Hashad Y; Whitcup SM;
    BMC Ophthalmol; 2015 Oct; 15():150. PubMed ID: 26519345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of dexamethasone intravitreal implant for refractory and treatment-naive diabetic macular edema in Taiwanese patients.
    Wang JK; Huang TL; Hsu YR; Chang PY
    J Chin Med Assoc; 2021 Mar; 84(3):326-330. PubMed ID: 33433135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.